上海莱士：8月28日召开董事会会议

Core Viewpoint - Shanghai Laishi (SZ 002252) announced its sixth board meeting on August 28, 2025, where it reviewed the full and summary reports for the first half of 2025 [1] Company Summary - For the year 2024, Shanghai Laishi's revenue composition is as follows: blood products production and sales account for 98.48%, testing equipment and reagents account for 1.48%, and other businesses account for 0.03% [1] - As of the report, Shanghai Laishi has a market capitalization of 45.7 billion yuan [1]